Within this bleak picture there are several bright spots???notably a large opportunity for generics especially in Japan, continuing growth in emerging markets such as India and China as well as a number of smaller markets, new waves of disease-modifying therapies for diabetes and immunologic diseases, and broader use of biologics where serious generic competition is about three years away in Europ